(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/074011 A1

(51) International Patent Classification:
A61K 31/4184 (2006.01) *A61K 9/00* (2006.01)
A61K 31/506 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2021/077466

(22) International Filing Date:
05 October 2021 (05.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20306154.4 05 October 2020 (05.10.2020) EP

(71) Applicant: **PIERRE FABRE MEDICAMENT** [FR/FR]; Les Cauquillous, 81500 Lavaur (FR).

(72) Inventors: **VEDOVATO, Jean-Claude**; 2 avenue des Sangliers, 60300 Senlis (FR). **SUISSA, Jeanne**; 74 boulevard du Président Wilson, 06600 Antibes (FR). **PROVENDIER, Olivier**; 72 bis rue de Plaisance, 92250 La Garenne (FR).

(74) Agent: **REGIMBEAU**; 20, rue de Chazelles, 75847 Paris Cedex 17 (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2022/074011 A1

(54) Title: COMBINATION OF ENCORAFENIB AND BINIMETINIB AS ADJUVANT TREATMENT FOR RESECTED STAGE II MELANOMA

(57) Abstract: The present invention relates to a pharmaceutical combination for use as adjuvant treatment after resection of a melanoma, wherein the melanoma which has been resected is stage II melanoma, and wherein the pharmaceutical combination comprises therapeutically effective amounts, independently, of: a) encorafenib or a pharmaceutically acceptable salt thereof; b) binimetinib or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier.